Cargando…

The Effect of FDA Drug Safety Communications on Patterns of Tiotropium Dispensing: A U.S. Health Plan Claims Database Study

BACKGROUND: The FDA issued 2 main drug safety communications (DSCs) on the cardiovascular safety of tiotropium in March 2008 (warning of a potential increased stroke risk) and January 2010 (informing of an absence of a significant increased stroke risk or cardiovascular events based on findings from...

Descripción completa

Detalles Bibliográficos
Autores principales: Major, Jacqueline M., Zhou, Esther H., Ding, Yulan, Ly, Thomas, Li, Jie, Pinheiro, Simone P., Seymour, Sally
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398184/
https://www.ncbi.nlm.nih.gov/pubmed/29952703
http://dx.doi.org/10.18553/jmcp.2018.24.7.700
_version_ 1785084018853675008
author Major, Jacqueline M.
Zhou, Esther H.
Ding, Yulan
Ly, Thomas
Li, Jie
Pinheiro, Simone P.
Seymour, Sally
author_facet Major, Jacqueline M.
Zhou, Esther H.
Ding, Yulan
Ly, Thomas
Li, Jie
Pinheiro, Simone P.
Seymour, Sally
author_sort Major, Jacqueline M.
collection PubMed
description BACKGROUND: The FDA issued 2 main drug safety communications (DSCs) on the cardiovascular safety of tiotropium in March 2008 (warning of a potential increased stroke risk) and January 2010 (informing of an absence of a significant increased stroke risk or cardiovascular events based on findings from a large trial). OBJECTIVE: To describe the effect of the FDA DSCs on medication dispensing of tiotropium in a large U.S. claims database. METHODS: Initiation of tiotropium products among patients with chronic obstructive pulmonary disease (COPD) aged 40 years and older was determined monthly from 2006-2012 using medication dispensing from the IMS Lifelink Health Plan Claims Database. Similarly, monthly initiation of products containing long-acting beta-agonists (LABAs) was calculated to explore product switching. The effect of the 2008 and 2010 FDA DSCs was measured using interrupted time-series analysis. Subgroups of patients with greater cardiovascular risk were also examined. RESULTS: A decreasing trend in initiation of tiotropium-containing products was present before the initial 2008 DSC. The decline in tiotropium initiation continued until January 2010, accompanied by an increased initiation of LABA-containing products in patients with COPD. In the presence of the existing decreasing trend, the initial DSC was followed by an immediate 2.8% (P = 0.02) further reduction in tiotropium initiation. Tiotropium initiation increased 2.5% (P = 0.03) immediately after the 2010 DSC, reducing the overall decline in rate and stabilizing (flattening) the trend. No significant changes in dispensing level or trend were observed among COPD patients with cardiovascular comorbidity. CONCLUSIONS: Cardiovascular safety concerns may have affected tiotropium initiation as indicated by the decrease in tiotropium dispensing shown immediately following the initial DSC. The effect was alleviated as concerns lessened following the most recent DSC.
format Online
Article
Text
id pubmed-10398184
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Academy of Managed Care Pharmacy
record_format MEDLINE/PubMed
spelling pubmed-103981842023-08-04 The Effect of FDA Drug Safety Communications on Patterns of Tiotropium Dispensing: A U.S. Health Plan Claims Database Study Major, Jacqueline M. Zhou, Esther H. Ding, Yulan Ly, Thomas Li, Jie Pinheiro, Simone P. Seymour, Sally J Manag Care Spec Pharm Research BACKGROUND: The FDA issued 2 main drug safety communications (DSCs) on the cardiovascular safety of tiotropium in March 2008 (warning of a potential increased stroke risk) and January 2010 (informing of an absence of a significant increased stroke risk or cardiovascular events based on findings from a large trial). OBJECTIVE: To describe the effect of the FDA DSCs on medication dispensing of tiotropium in a large U.S. claims database. METHODS: Initiation of tiotropium products among patients with chronic obstructive pulmonary disease (COPD) aged 40 years and older was determined monthly from 2006-2012 using medication dispensing from the IMS Lifelink Health Plan Claims Database. Similarly, monthly initiation of products containing long-acting beta-agonists (LABAs) was calculated to explore product switching. The effect of the 2008 and 2010 FDA DSCs was measured using interrupted time-series analysis. Subgroups of patients with greater cardiovascular risk were also examined. RESULTS: A decreasing trend in initiation of tiotropium-containing products was present before the initial 2008 DSC. The decline in tiotropium initiation continued until January 2010, accompanied by an increased initiation of LABA-containing products in patients with COPD. In the presence of the existing decreasing trend, the initial DSC was followed by an immediate 2.8% (P = 0.02) further reduction in tiotropium initiation. Tiotropium initiation increased 2.5% (P = 0.03) immediately after the 2010 DSC, reducing the overall decline in rate and stabilizing (flattening) the trend. No significant changes in dispensing level or trend were observed among COPD patients with cardiovascular comorbidity. CONCLUSIONS: Cardiovascular safety concerns may have affected tiotropium initiation as indicated by the decrease in tiotropium dispensing shown immediately following the initial DSC. The effect was alleviated as concerns lessened following the most recent DSC. Academy of Managed Care Pharmacy 2018-07 /pmc/articles/PMC10398184/ /pubmed/29952703 http://dx.doi.org/10.18553/jmcp.2018.24.7.700 Text en Copyright © 2018, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research
Major, Jacqueline M.
Zhou, Esther H.
Ding, Yulan
Ly, Thomas
Li, Jie
Pinheiro, Simone P.
Seymour, Sally
The Effect of FDA Drug Safety Communications on Patterns of Tiotropium Dispensing: A U.S. Health Plan Claims Database Study
title The Effect of FDA Drug Safety Communications on Patterns of Tiotropium Dispensing: A U.S. Health Plan Claims Database Study
title_full The Effect of FDA Drug Safety Communications on Patterns of Tiotropium Dispensing: A U.S. Health Plan Claims Database Study
title_fullStr The Effect of FDA Drug Safety Communications on Patterns of Tiotropium Dispensing: A U.S. Health Plan Claims Database Study
title_full_unstemmed The Effect of FDA Drug Safety Communications on Patterns of Tiotropium Dispensing: A U.S. Health Plan Claims Database Study
title_short The Effect of FDA Drug Safety Communications on Patterns of Tiotropium Dispensing: A U.S. Health Plan Claims Database Study
title_sort effect of fda drug safety communications on patterns of tiotropium dispensing: a u.s. health plan claims database study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398184/
https://www.ncbi.nlm.nih.gov/pubmed/29952703
http://dx.doi.org/10.18553/jmcp.2018.24.7.700
work_keys_str_mv AT majorjacquelinem theeffectoffdadrugsafetycommunicationsonpatternsoftiotropiumdispensingaushealthplanclaimsdatabasestudy
AT zhouestherh theeffectoffdadrugsafetycommunicationsonpatternsoftiotropiumdispensingaushealthplanclaimsdatabasestudy
AT dingyulan theeffectoffdadrugsafetycommunicationsonpatternsoftiotropiumdispensingaushealthplanclaimsdatabasestudy
AT lythomas theeffectoffdadrugsafetycommunicationsonpatternsoftiotropiumdispensingaushealthplanclaimsdatabasestudy
AT lijie theeffectoffdadrugsafetycommunicationsonpatternsoftiotropiumdispensingaushealthplanclaimsdatabasestudy
AT pinheirosimonep theeffectoffdadrugsafetycommunicationsonpatternsoftiotropiumdispensingaushealthplanclaimsdatabasestudy
AT seymoursally theeffectoffdadrugsafetycommunicationsonpatternsoftiotropiumdispensingaushealthplanclaimsdatabasestudy
AT majorjacquelinem effectoffdadrugsafetycommunicationsonpatternsoftiotropiumdispensingaushealthplanclaimsdatabasestudy
AT zhouestherh effectoffdadrugsafetycommunicationsonpatternsoftiotropiumdispensingaushealthplanclaimsdatabasestudy
AT dingyulan effectoffdadrugsafetycommunicationsonpatternsoftiotropiumdispensingaushealthplanclaimsdatabasestudy
AT lythomas effectoffdadrugsafetycommunicationsonpatternsoftiotropiumdispensingaushealthplanclaimsdatabasestudy
AT lijie effectoffdadrugsafetycommunicationsonpatternsoftiotropiumdispensingaushealthplanclaimsdatabasestudy
AT pinheirosimonep effectoffdadrugsafetycommunicationsonpatternsoftiotropiumdispensingaushealthplanclaimsdatabasestudy
AT seymoursally effectoffdadrugsafetycommunicationsonpatternsoftiotropiumdispensingaushealthplanclaimsdatabasestudy